000140284 001__ 140284
000140284 005__ 20240613151933.0
000140284 0247_ $$2doi$$a10.1016/j.neurol.2018.07.001
000140284 0247_ $$2pmid$$apmid:30098799
000140284 0247_ $$2ISSN$$a0035-3787
000140284 0247_ $$2ISSN$$a2213-0004
000140284 0247_ $$2altmetric$$aaltmetric:70398201
000140284 037__ $$aDZNE-2020-06606
000140284 041__ $$aEnglish
000140284 082__ $$a610
000140284 1001_ $$0P:(DE-2719)2811373$$aHöglinger, G. U.$$b0$$eFirst author$$udzne
000140284 245__ $$aNew classification of tauopathies.
000140284 260__ $$aIssy-les-Moulineaux$$bElsevier Masson$$c2018
000140284 264_1 $$2Crossref$$3print$$bElsevier BV$$c2018-11-01
000140284 3367_ $$2DRIVER$$aarticle
000140284 3367_ $$2DataCite$$aOutput Types/Journal article
000140284 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1718284726_11707$$xReview Article
000140284 3367_ $$2BibTeX$$aARTICLE
000140284 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000140284 3367_ $$00$$2EndNote$$aJournal Article
000140284 520__ $$aTauopathies are a group of neurodegenerative diseases characterized by pathological intracellular deposits of the protein tau. Isoform composition, morphology and anatomical distribution of cellular tau-immunoreactivities are defining distinct tauopathies as molecular pathological disease entities. The clinical spectrum of tauopathies includes syndromes with primary motor symptoms and with primary cognitive dysfunction. The traditional syndrome-based classification is currently being complemented by a molecular-pathological classification. While the syndrome-based classification is helpful to select symptomatic therapies, and to generate clinical working hypotheses about underlying etiologies, the molecular-pathological classification is most important for the development and application of molecularly tailored disease-modifying therapies.
000140284 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000140284 542__ $$2Crossref$$i2018-11-01$$uhttps://www.elsevier.com/tdm/userlicense/1.0/
000140284 588__ $$aDataset connected to CrossRef, PubMed,
000140284 650_2 $$2MeSH$$aHumans
000140284 650_2 $$2MeSH$$aNeurodegenerative Diseases: classification
000140284 650_2 $$2MeSH$$aNeurodegenerative Diseases: genetics
000140284 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: classification
000140284 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: genetics
000140284 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: physiopathology
000140284 650_2 $$2MeSH$$aTauopathies: classification
000140284 650_2 $$2MeSH$$aTauopathies: genetics
000140284 650_2 $$2MeSH$$aTauopathies: physiopathology
000140284 7001_ $$0P:(DE-2719)2811600$$aRespondek, G.$$b1$$udzne
000140284 7001_ $$aKovacs, G. G.$$b2
000140284 77318 $$2Crossref$$3journal-article$$a10.1016/j.neurol.2018.07.001$$b : Elsevier BV, 2018-11-01$$n9$$p664-668$$tRevue Neurologique$$v174$$x0035-3787$$y2018
000140284 773__ $$0PERI:(DE-600)2036356-4$$a10.1016/j.neurol.2018.07.001$$gVol. 174, no. 9, p. 664 - 668$$n9$$p664-668$$q174:9<664 - 668$$tRevue neurologique$$v174$$x0035-3787$$y2018
000140284 8564_ $$uhttps://pub.dzne.de/record/140284/files/DZNE-2020-06606_Restricted.pdf
000140284 8564_ $$uhttps://pub.dzne.de/record/140284/files/DZNE-2020-06606_Restricted.pdf?subformat=pdfa$$xpdfa
000140284 909CO $$ooai:pub.dzne.de:140284$$pVDB
000140284 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000140284 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811600$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000140284 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000140284 9141_ $$y2018
000140284 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bREV NEUROL-FRANCE : 2021$$d2022-11-25
000140284 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-25
000140284 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-25
000140284 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-25
000140284 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-25
000140284 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-25
000140284 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-25
000140284 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-25
000140284 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-25
000140284 9201_ $$0I:(DE-2719)1110002$$kAG Höglinger 1$$lTranslational Neurodegeneration$$x0
000140284 980__ $$ajournal
000140284 980__ $$aVDB
000140284 980__ $$aI:(DE-2719)1110002
000140284 980__ $$aUNRESTRICTED